QPPV.COM KNOWLEDGE ASSESSMENT

Bispecific and Multispecific Antibodies: Biology, Clinical Development and Pharmacovigilance

Test your understanding of the concepts covered by Bispecific and Multispecific Antibodies: Biology, Clinical Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A dual-pathway bispecific produces an adverse reaction not seen with either parental antibody alone. What is the best initial safety interpretation?

The event must be unrelated because each individual target is already clinically characterised The event may reflect additive, synergistic or qualitatively new effects from simultaneous target engagement The event proves that the product is contaminated The event should be assigned automatically to the target with the higher affinity

Question 2 of 10 Why does conditional targeting based on co-expression of two antigens require evidence beyond the design concept?

Co-expression is always identical in healthy and diseased tissues Functional selectivity depends on actual expression density, accessibility, spatial organisation and geometry Conditional targeting eliminates the need for non-clinical studies Avidity is independent of antigen density

Question 3 of 10 Why can a small Fc-free T-cell engager still present substantial systemic risk?

Small size guarantees rapid accumulation in all tissues Short plasma half-life prevents inflammatory effects Potent cell-bridging can trigger rapid immune activation, including self-amplifying inflammatory responses Fc-free molecules are intrinsically more immunogenic than all IgG-like molecules

Question 4 of 10 Which statement best explains the importance of manufacturing-change traceability for a bispecific antibody?

Manufacturing changes cannot affect clinical safety if the amino-acid sequence is unchanged Traceability allows possible changes in binding, potency, immunogenicity or unintended immune activation to be investigated by product period and batch Batch information is relevant only for counterfeit investigations Spontaneous reports always contain sufficient batch information for comparability assessment

Question 5 of 10 A coagulation result appears inconsistent with the patient’s clinical status during treatment with a cofactor-mimicking bispecific. What should the safety review first investigate?

Whether the product has lost both binding activities Whether the assay principle is affected by the molecule and whether the result influenced clinical decisions Whether CRS grading was performed using an oncology scale Whether the product was administered by infusion rather than injection

Question 6 of 10 Why should all neurological adverse-event terms reported with a bispecific not automatically be classified as ICANS?

ICANS is unrelated to immune-effector therapies Neurological manifestations may have alternative or contributing causes, including infection, metabolic abnormalities, CNS disease or concomitant medicines ICANS can occur only after permanent treatment discontinuation Preferred terms always provide more clinical information than medical review

Question 7 of 10 Which development approach is most appropriate when no conventional animal species reproduces both target interactions adequately?

Proceed without non-clinical evidence because the molecule is engineered Rely exclusively on toxicity findings from a species that binds only one target Integrate relevant-species or surrogate studies with human-cell assays, tissue studies, modelling and clinical risk controls as appropriate Use the maximum tolerated dose from an unrelated monospecific antibody

Question 8 of 10 Which statement best characterises the non-clinical relevance of an animal species for a bispecific antibody?

Species relevance is established if either binding arm recognises its target A species is informative only when both required target engagements and their functional consequences are sufficiently comparable Any primate study is automatically predictive for a bispecific antibody A species is relevant if the product has an Fc region, regardless of target binding

Question 9 of 10 Which factor would be least relevant when assessing the likelihood and severity of CRS with a T-cell-engaging bispecific?

Tumour burden and circulating target-cell burden The exact dose and position within a step-up sequence Binding geometry and affinity of the two arms Whether the molecule has two binding specificities rather than one, irrespective of its mechanism

Question 10 of 10 Which example most clearly illustrates why a bispecific safety model must be mechanism-specific rather than oncology-focused?

A CD3-engaging product causing T-cell activation A molecule that binds activated factor IX and factor X to mimic part of factor VIII function A tumour-targeting molecule causing rapid tumour-cell killing A product with a step-up dosing schedule

Bispecific and Multispecific Antibodies: Biology, Clinical Development and Pharmacovigilance

Cookie Settings